US Pharma MarketingMerck scraps a Phase 2 Alzheimer
Merck ends a Phase 2 Alzheimer Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy…
Merck has axed a Phase 2 trial testing an experimental Alzheimer’s medicine, Endpoints News has learned.
The company terminated a mid-stage test of the oral drug candidate MK-1167, a Merck spokesperson ...
Source: Endpoints News